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ABSTRACT
Integrating nanomaterials with biological entities has led to the development of diagnostic tools 
and biotechnology-derived therapeutic products. However, to optimise the design of these 
hybrid bionanomaterials, it is essential to understand how controlling the biological 
interactions will influence desired outcomes. Ultimately, this knowledge will allow more rapid 
translation from the bench to the clinic. In this paper, we developed a micellar system that was 
assembled using modular antibody-polymer amphiphilic materials. The amphiphilic nature was 
established using either polyethylene glycol (PEG) or a single-chain variable fragment (scFv) 
from an antibody as the hydrophile, and a thermoresponsive polymer (poly(oligoethylene 
glycol) methyl ether methacrylate) as the hydrophobe. By varying the ratios of these 
components, a series of nanoparticles with different antibody content was self-assembled, 
where the surface presentation of targeting ligand was carefully controlled. In vitro and in vivo 
analysis of these systems identified a mismatch between the optimal targeting ligand density 
to achieve maximum cell association in vitro compared to tumour accumulation in vivo. For 
this system, we determined an optimum antibody density for both longer circulation and 
enhanced targeting to tumours that balanced stealthiness of the particle (to evade immune 
recognition as determined in both mouse models and in whole human blood) with enhanced 
accumulation achieved through receptor binding on tumour cells in solid tumours. This 
approach provides fundamental insights into how different antibody densities affect the 
interaction of designed nanoparticles with both target cells and immune cells, thereby offering 
a method to probe the intricate interplay between increased targeting efficiency versus the 
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Nanomedicines are now evolving as precisely engineered nanomaterials that offer significant 
potential to overcome many limitations of conventional anti-cancer drugs.1 The therapeutic 
efficacies of current drugs are limited due to unfavourable physicochemical properties such as 
low solubility, instability, toxicity issues due to lack of selectivity, and poor pharmacokinetics. 
In contrast, the properties of new nanomaterials can be designed to enhance biocompatibility, 
reduce toxicity, control drug release, and increase circulation time in the body, enabled much 
improved therapeutic delivery.2 Furthermore, nanomaterials offering theranostic features can 
enable real-time monitoring of site-specific drug delivery to the cancer target.3 Although 
nanomaterials have been intensively investigated for delivering drugs to the solid tumours, 
there are studies showing discrepancies with the number of nanoparticles reaching tumour sites 
versus the administered nanoparticle dose. In a meta-analysis of a wide range of nanomedicines 
administered to mice, it was suggested that on average only 0.7% of the injected dose is retained 
in the solid tumours, indicating the exceptional challenge for translation of nanomedicines.4 
In order to enhance delivery efficiency, it is vital to understand the factors that influence the 
pharmacokinetic profile and behaviour of nanomaterials. Upon intravenous administration, 
nanoparticles initially interact with blood components before distributing throughout the 
various tissues, including the target tumour site. Longer blood circulation times are a critical 
factor in achieving successful tumour accumulation, which ultimately depends on how well 
nanoparticles overcome the biological barriers and clearance systems designed to exclude and 
remove exogenous materials. For nanomaterials, a major problem is rapid coating by opsonin 
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residence times of nanoparticles can be influenced by their physicochemical properties such as 
shape, surface charge, size, and ligand densities.7 Nonetheless, an in-depth analysis of the 
relationships between physicochemical properties, body clearance and the overall targeting 
efficacies of nanoparticles has yet to be conducted and correlated fully across a coherent set of 
particles.
Research to date has established some rules for consideration when designing nanomaterials 
for drug delivery. For example, it is well reported that nanoparticle sizes in the range of 20 – 
30 nm results in higher receptor-mediated uptake, while nanoparticles in the 20 – 100 nm range 
can be used for enhanced liver accumulation.8 However, there is by no means a consensus in 
the literature as to what is the most ideal size of particle for optimal therapeutic efficiency and 
most nanoparticle strategies develop materials that span particle sizes between 20-200 nm. It 
is also well established (but not precisely quantified) that “targeted” nanomaterials show 
greater uptake and accumulation in cells, mostly under in vitro conditions. Often when these 
studies are translated to animals, however, incorporating a higher density of targeting protein 
functionality to enhance recognition at an intended disease site increases immune recognition 
and expedites clearance of nanomaterials; in some cases, such modulation with targeting 
ligands can actually decrease the tumour accumulation compared to the untargeted 
nanomedicine.9 Despite the wealth of data on new and sophisticated drug delivery vehicles, 
there are significant exceptions to these generalised rules, and there is no clear methodology 
for optimising targeting approaches for these materials.10 Furthermore, these generalised rules 
that often are used to design new materials seldom transfer between the bench, the cell in a 
dish, and the body, leading to a disconnect between materials design and observed properties.9 
One point of significant interest is the influence of targeting ligand density on nanomaterial 
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density of ligands influence the internalisation and subsequent cellular processing of 
bionanomaterials, but there is limited information on how the surface density of ligands affects 
the physiological behaviour of nanomaterials in circulation, and how this ultimately translates 
to tumour accumulation.12,13 Nonetheless, the limited data available suggests that there is a 
threshold at which clustering of ligands saturates surface receptors, often leading to modified 
internalisation pathways and variable efficacy of delivered therapeutics.14,15 The challenge is 
to develop strategies to design next-generation nanomaterials, accounting for the competing 
requirements of enhanced cellular uptake through higher ligand density, with embedded 
“stealthiness” to avoid rapid immune recognition and clearance. This epitomises the general 
observation that what is evidenced in vitro, is difficult to transition to in vivo, due to the absence 
of the competing requirement for stealthiness in the majority of in vitro assays.
To date, the majority of studies looking at receptor clustering effects have focused on the effect 
of small molecule ligands, such as the folate receptor.16 One reason for this is the intrinsic 
complexity associated with biomolecule assemblies, complicating the development of well-
defined systems where this effect can be monitored universally. This project progresses our 
understanding of targeting in a complex biological environment, through the development of 
micellar systems specifically designed to control the targeting ligand density of more 
biologically relevant protein-based ligands through the self-assembly process. This is achieved 
using thermoresponsive polymers, which can interact with the proteins in aqueous conditions 
without denaturing them. 
In this study, we synthesised an amphiphilic antibody-polymer conjugate that was self-
assembled to form micelles in which the surface constitutes a defined mixture of stealthy 
polymers and an antibody fragment (single-chain variable fragment – scFv) that shows high 






























































Page 6 of 48
relatively small size of scFvs avoids steric effects associated with whole monoclonal 
antibodies, affording greater control over packing density, while the polymeric materials offer 
well-understood physicochemical tuneability that is required to develop such complex, yet 
ordered systems. By modulating the incorporation of antibody-polymer hybrid amphiphiles 
through co-assembly with purely synthetic polymer amphiphiles, the density of antibody 
fragments on the micelle can be manipulated across a significant range. Hence, the effect of 
ligand density on how the micelles bind to cell surface receptors and how it dictates the cellular 
uptake pathways of particular nanomaterials can be investigated. This can then be compared to 
the ultimate biological fate of the micelles upon injection into tumour-bearing mice, where the 
nanoparticles are exposed to a greater complement of biological barriers that limit tumour 
accumulation. This offers a robust approach to develop an in-depth understanding of how these 
fundamental properties can be utilised to enhance cellular uptake and influence biodistribution. 
Figure 1 schematically represents the hypothesis of this study, that increased antibody will lead 
to maximum binding efficiency in vitro, but also leads to greater immune recognition that often 
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Figure 1. Schematic diagram postulating the influence of ligand density on nanoparticle uptake 
in vitro and in vivo. An optimum ratio of antibody to PEG components on micelles may lead 
to an improvement in the therapeutic efficacy due to enhanced targeting and lower immune 
response.
RESULTS AND DISCUSSION
We set out to design a nanomaterial system where precise control over the ratio of antibody 
and PEG components could be achieved, allowing us to synthesise a range of micelles 
incorporating various antibody densities so we could understand their biological fate. The 






























































crosslinking the final micellar assemblies. 4-cyano-4-
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(ethylsulfanylthiocarbonylsulfanyl)pentanoic acid (CEPA) was employed as the reversible 
addition-fragmentation chain transfer (RAFT) agent to provide control over the radical 
copolymerisation of these two monomers as well as impart acid chain-end functionality that 
could then be modified with a dibenzocyclooctyne (DBCO) amine linker for downstream 
coupling of the solvent-sensitive antibody fragments through strain promoted alkyne azide 
cycloaddition (SPAAC).18 The generalised scheme and selective characterisation of each 
8
advances. First, a synthetic component was required that could be coupled with proteins under 
aqueous conditions (i.e. water-soluble), but which would also act as the hydrophobe for 
assembly into micelles. It was also necessary to have a mechanism to crosslink the hydrophobic 
core for enhanced stability of the assemblies. Second, a suitable mechanism for coupling the 
antibody fragment to the hydrophobe was needed, as well as a defined way of tracking 
successful incorporation of the different components into the assemblies. 
Thermoresponsive, crosslinkable polymer chain as the hydrophobic component. A key 
challenge in the development of amphiphilic polymer-protein conjugates is the stringent 
reaction conditions required for antibody modifications. For example, such reactions cannot be 
undertaken in organic solvents (as this leads to loss of tertiary structure); however in water 
hydrophobic polymers are not soluble, and heterogeneous conjugation is poor yielding and 
uncontrolled.17 Thus, we sought to develop a thermoresponsive “hydrophobic” component for 
the amphiphilic system using di(ethylene glycol) methyl ether methacrylate (DEGMA) and 
pentafluorophenyl methacrylate (MAPFP) in which coupling to the antibody can be undertaken 
in water at low temperature, but upon an increase in temperature above the lower critical 
solution temperature (LCST) the polymer becomes insoluble. To this end, we sought to develop 







































































1 p(DEGMA-co-MAPFP) 6.0 1.30 92 10
2 p(DEGMA-co-MACYS) 5.5 1.50 85 16
3 DBCO-p(DEGMA-co-MACYS) 6.5 1.60 82 16
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a Molecular weight obtained by SEC analysis in THF using PS standards. b Dispersity (ĐM) 
obtained by SEC analysis in THF using PS standards. c Onset temperature of the 
thermoresponsive transition.
A key element of our design was to ensure the stability of these micelles, both during in vitro 
and in vivo evaluation. To this end, we incorporated sulfhydryl units within the polymer chains 
to allow for disulfide-mediated crosslinking between polymer chains within the final micellar 
assemblies. The pentafluorophenyl (PFP) group within the copolymer was subsequently 
modified to present thiol groups through post-polymerisation modification with cysteamine 
(CYS).19 Near quantitative substitution of the pentafluorophenyl groups with CYS to form 
p(DEGMA-co-MACYS) was achieved using the polar aprotic solvent N,N-dimethylformamide 
9
component is presented in Figure 2A. Using CEPA, statistical copolymers of p(DEGMA-co-
MAPFP) were synthesised with defined molecular weights and dispersities (Table 1). The 
molecular weights of p(DEGMA-co-MAPFP) were calculated using 1H NMR by integrating 
the DEGMA side-chain protons at 4.01 − 4.24 ppm (for DEGMA contribution), the p(MAPFP) 
and p(DEGMA) methyl protons at 0.8 − 1.28 ppm and subtracting the contribution from 
DEGMA (to calculate the MAPFP contribution), and calibrating to the methylene protons 
adjacent to the terminal trithiocarbonate (3.22 ppm). 1H and 19F NMR spectra of the 
p(DEGMA-co-MAPFP) copolymer can be seen in Figure 2B and 2C, respectively, and SEC 
results are shown in Table 1.
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(DMF), which is well-known to promote SN2 substitution reactions.20 This process was 
monitored through the disappearance of the fluorine peaks (-151.7, -152.7 (ortho), -158.2 
(para), and -163.3 (meta) ppm) in the 19F NMR spectrum of the polymer (Figure 2C) following 
amidation. Successful coupling of CYS to the polymer was also observed indirectly, with a 
significant change in the polymer LCST following modification (Table 1). The LCST onset 
temperature shifted from 10 °C to 16 °C upon CYS modification (Figure S2), presumably due 
to modulation of the overall copolymer hydrophobicity through replacement of the PFP group 
with the more hydrophilic thiol. Moreover, these thiol groups present potential crosslinking 
sites initiated through disulfide formation that would exhibit redox responsiveness for 
downstream application of these nanomaterials in drug delivery.21
The final step in the preparation of the responsive hydrophobic component of the amphiphile 
was chain-end modification to facilitate rapid conjugation of either the biological entity or PEG 
hydrophile, followed by incorporation of a fluorescent dye (Cy5 maleimide) for tracking 
purposes. The DBCO-p(DEGMA-co-MACYS) copolymer were conveniently prepared 
through amidation with a heterobifunctional linker (Figure 2).22 Successful modification was 
monitored by UV-Vis spectroscopy with the appearance of the characteristic absorbance peak 
of DBCO at 309 nm (Figure 2D) and 1H NMR which showed the presence of aromatic peaks 
between 7.3 – 7.65 ppm assigned to DBCO (Figure S1). 
10
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Figure 2. (A) Reaction scheme showing the synthesis of the thermoresponsive, crosslinkable 
polymer chain for the hydrophobic component of the amphiphiles (B) 1H NMR (500 MHz, 
CDCl3) spectrum of p(DEGMA-co-MAPFP) with (a) methylene protons adjacent to the 
trithiocarbonate, (b) (DEGMA) side-chain protons, and (c) p(MAPFP) and p(DEGMA) methyl 
protons. (C) 19F NMR (470 MHz, CDCl3) spectra of p(DEGMA-co-MAPFP) copolymer 
exhibiting the ortho-, meta-, and para- signals associated with the PFP repeat units (black), and 
after reaction of the polymer with CYS resulting in p(DEGMA-co-MACYS) copolymer (blue) 
indicating almost complete success of the amidation reaction. (D) UV-Vis spectra in methanol 
of DBCO amine (purple), p(DEGMA-co-MACYS) (blue) and DBCO-p(DEGMA-co-
MACYS) (red) showing the incorporation of DBCO and Cy5 peaks at 309 and 647 nm 
respectively.
11
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This was followed by conjugation of Cy5 maleimide dye onto a small portion of the thiol 
groups in the polymer to provide a diagnostic handle for the hydrophobic block, and the 
subsequent product was characterised using UV-Vis spectroscopy, which showed the 
characteristic absorbance peak of Cy5 at 647 nm. The LCST of the resulting polymer system 
was evaluated and shown to be 16 °C, suggesting that successful protein conjugation could 
occur at temperatures below this point when the polymer was soluble in water, but subsequent 
heating above this point would lead to self-assembly of the polymer chains (Figure S2). Table 
1 summarises the physicochemical properties of the hydrophobic component after subsequent 
modifications.
Development of amphiphilic conjugates. The thermoresponsive “hydrophobic” polymer 
described above was then coupled with either scFv-N3 or PEG-N3 hydrophiles through SPAAC 
reaction, a fast catalyst-free click chemistry method, as a convenient route to creating 
amphiphilic block copolymers.18 As a model antibody system, an scFv (25 kDa) of the 
established Prostate-Specific Membrane Antigen (PSMA) targeting antibody, J591, was 
engineered and produced in bacteria.23 Moreover, an unnatural amino acid containing azide 
functionality was engineered into the N-terminus of the scFv to allow convenient azide-alkyne 
click reactions to occur.24 The scFv was subsequently conjugated to DBCO-p(DEGMA-co-
MACYS) by incubation in PBS at 4 °C for 24 h resulting in the formation of hybrid conjugates 
(scFv-p(DEGMA-co-MACYS)). After conjugation, these amphiphiles were kept at 30 °C for 
10 min, leading to insolubility of the thermoresponsive chain. Subsequent centrifugation 
(14,100 rcf for 10 min) led to precipitation and formation of a hybrid conjugate pellet, while 
unbound scFvs remained in the supernatant and could be removed. The pellet was then 
redispersed into PBS and centrifuged with Amicon® Spin filters (MWCO: 30 kDa) to remove 
any unbound polymer from the hybrid conjugate. The resulting hybrid conjugates were 
12
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Figure 3. (A) Schematic representation of the structures of both the mPEG and scFv hybrid 
conjugates. (B) SEC chromatogram of the mPEG-polymer conjugate (red) along with starting 
materials, mPEG-N3 (orange) and DBCO-p(DEGMA-co-MACYS) polymer (black). (C) 
HPLC chromatogram of the hybrid conjugate (dark green) along with controls, J591 scFv-N3 
(light green) and DBCO-p(DEGMA-co-MACYS) polymer (black).
A similar procedure was used to develop the polymer conjugate (mPEG-p(DEGMA-co-
MACYS)), in which DBCO-p(DEGMA-co-MACYS) was incubated with commercially-
13
     
     
evaluated using HPLC analysis (Figure 3C), and the obtained result is consistent with 
successful antibody conjugation to the synthetic hydrophobe.25 Successful conjugation was 
further validated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis (Figure S3), where the archetypical smearing of the conjugate (lane 4), rather 
than single sharp band as observed for the scFv alone (lane 2), was indicative of scFv coupling 
to the synthetic copolymer. The elongated and “smeared” peak was present in SDS PAGE for 
both Coomassie blue and Cy5 channels (labelling of both the protein and the polymer 
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available methoxy-PEG (mPEG) azide in water at 4 °C for 24 h. mPEG has been widely used 
to improve the therapeutic index of clinical drugs,28 and formulations such as mPEG modified 
liposomal doxorubicin (Doxil / Caelyx) are accepted by the Food and Drug Administration 
(FDA) for the treatment of breast cancer.29 In order to prevent recognition by the mononuclear 
phagocytic system (MPS) and thereby impart stealth properties to the micelles, mPEG 
displaying a radius of hydration (RH) of 4 nm similar to the scFv (Figure S4), was used to form 
mPEG conjugates, with successful coupling demonstrated by size exclusion chromatography 
(Figure 3B).
The cellular association of the monomeric conjugates with prostate cancer cells that had high 
(PC3-PIP cells: PSMA+) and low (PC3 cells: PSMA-) levels of PSMA expressions were 
assessed to demonstrate targeting ability of the conjugates.30 Flow cytometry analysis of the 
conjugates following incubation at 4 °C (when the chains would be in their soluble form) 
showed significantly higher association for the hybrid conjugates in PSMA+ cells compared to 
the polymer conjugate (Figure S5). Likewise, in the cells that showed low expression of PSMA 
(PSMA-), much lower association was observed for both conjugates, indicating that the 
mechanism of association was likely via receptor-mediated interactions. Importantly, this 
preliminary in vitro study suggested that the coupling approach still facilitated successful 
presentation of the scFv for binding to the receptor.
Synthesis of micellar assemblies. Micelles were synthesised with varying antibody densities 
by mixing the amphiphilic hybrid conjugates with the polymer conjugates in PBS at 
temperatures below the LCST (16 °C), then increasing the temperature above the LCST, 
whereupon the thermoresponsive behaviour of the hydrophobic component led to self-
assembly of the conjugates.31 This process is reversible, and as an example for purely polymer 
conjugates or hybrid conjugates, Figure 4 shows the size by dynamic light scattering (DLS) of 
14
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unimers (at 5 °C), their assembly into micelles at 25 °C, then subsequent destabilisation and 
existence of unimers when cooled back down to 5 °C. Importantly, this process was observed 
to occur for both the polymer and hybrid conjugates, with the size of the micelles being 
approximately 70 nm at 25 °C, irrespective of the hydrophile that was used, allowing for a 
decoupling of micelle size and composition; this was an important pre-requisite for future 
comparisons (Figure S6). In addition, the zeta potential of the micelles was found to be less 
affected by an increase in antibody density, with the overall charge remaining neutral 
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Figure 4. DLS size distribution of the micelles from polymer conjugate and hybrid conjugates. 
(A) non-crosslinked polymer micelles, (B) crosslinked polymer micelles by oxygen purging,
(C) non-crosslinked hybrid micelles, and (D) crosslinked hybrid micelles at 25 °C (red) and 5 
°C (green). The insert in 4B and 4D shows the TEM images of crosslinked micelles from 
polymer and hybrid conjugates respectively, indicating an average size of 70 nm. Oxygen 
purging results in crosslinking due to the formation of disulfide bonds between the thiol groups 
of the CYS side-chains.
The micelles were synthesised by mixing the PEG and hybrid conjugates in varying ratios. In 
order to characterise the amount of antibody components in micelles, a secondary system was 
developed, in which the hybrid conjugates were labelled with Cy5 and the polymer conjugates 
were labelled with RhodamineB (Figure S8).  The average PEG-antibody ratios for each system 
were calculated based on the relative fluorescence intensity of Cy5 (for antibody amphiphile) 
to RhodamineB (for polymer amphiphile) (Figure S9). The “theoretical” correction factor was 
calculated based on the feed ratio of antibody:polymer in the hybrids and was compared to the 
actual fluorescence that we determined using the fluorimeter (for the 4 formulations that had 
the highest fluorescence content, e.g. A100, A75, A50, A25) with < 5% difference between 
these two values. This implies that there were little or no quenching arising from intermolecular 
interactions in any of these micelle systems. In order to ensure that the micelles were stable 
under both in vitro and in vivo conditions, the assemblies were transiently crosslinked using 
disulfide chemistry.32 Crosslinking not only acts to lock in the structure of the low glass 
transition temperature hydrophobe (DEGMA) to prevent dynamic exchange of the individual 
micellar components but also ensures stability following intravenous (I.V.) injection, where 
this has been shown to significantly affect in vivo accumulation and biodistribution of 
nanomedicines.33,34 Here, the thiol-functional group in CYS acts as the crosslinking point by 
16
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forming disulfide bonds by oxidation through oxygen purging.35,36 Evaluation of the size of the 
micelles following oxidation showed crosslinked micelles retained their size even after 
reducing the temperature to below the LCST, suggesting that the micelles were locked in 
conformation (Figure 4B and 4D). TEM micrographs of both micelles are also shown in Figure 
4 (inset), confirming the size of the assemblies formed. The stability of purely synthetic 
micelles was further analysed in cell culture media containing foetal bovine serum (FBS) as 
pseudo-serum conditions, and the structures maintained integrity and size over 24 h (Figure 
S10). However, longer incubation of these micelles in 50% serum-containing media resulted 
in an increase in micelle size, most likely due to higher serum protein interactions (Figure S11). 
Importantly, there was no evidence of degradation of the micelles through observation of small 
fragments in the DLS.  Moreover, fluorescence stability of A0 micelles showed < 15% Cy5 
loss in 50% FBS media for an incubation of 48 h (Figure S12). The crosslinking of the micelles 
offers greater control over the material used for in vivo experiments and provides confidence 
that the interactions observed are due to micellar interactions, rather than interactions by 
fragments of the micelles.
Effect of ligand density on cellular association and internalisation. Micelles of varying 
scFv densities (0, 5, 10, 15, 25, 50, 75, 100% chain ratio relative to the PEG-hydrophile) were 
assembled to investigate the relationship between antibody density and cellular association and 
were labelled as A0, A5, A10, A15, A25, A50, A75, and A100, respectively (Figure 1). These 
micelles were incubated with prostate cancer cell lines that either had high expression of PSMA 
(PSMA+) or low expression (PSMA-) for 1 h prior to evaluation of cell binding by flow 
cytometry.30 Cellular association studies using flow cytometry demonstrated that even with a 
small increase in antibody density, micelles typically showed an increased association with 
PSMA+ cells. For these cells that upregulated PSMA, the cellular association was seen to rise 
17
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with increasing antibody content until reaching a plateau at 25-50% incorporation of antibody, 
before decreasing modestly at higher incorporation (Figure 5A). This may be due to the 
potential for receptor saturation, resulting from the interaction between higher amounts of 
scFvs with the PSMA receptors on the particular cell line. In addition to receptor saturation, 
the decrease in nanoparticle association might also be due to the competitive binding between 
micelles onto the receptors.37,38 Compared to 50% antibody micelles, 100% micelles have 
higher antibody content resulting in higher competition for interacting with the active site of 
the receptors, thereby hindering the cellular association.39-41 The association with PSMA- cells 
was low, indicating that specific interaction was negligible with receptors on this cell line. This 
has been further validated using a competition assay, where the PSMA+ cells exhibited 
significantly reduced cellular association with the targeted micelles when pre-incubated with 
free scFv (10 µg mL-1), compared to when treated with targeted micelles alone (Figure S13). 
To better understand the observed trend in receptor binding on PSMA+ cells, a binding assay 
was conducted to explore the effect of different concentrations of antibody containing micelles 
(A25 and A100) (Figure S14) on cellular association. Under these conditions, the number of 
micelles at each concentration were approximately the same for A25 and A100. A100 was 
found to bind to maximum number of cells (% cell association) at a lower concentration than 
A25 (25 µg/mL compared to 100 µg/mL, respectively), potentially due to the avidity effect of 
these nanoparticles (more antibodies to bind with receptors). And when both A25 and A100 
showed association with 100% of cells (100 µg/mL), the MFI was higher for A25 than A100. 
This suggests that at high concentrations, more of the nanoparticles with lower antibody density 
can bind to the cells than those with higher antibody density. Therefore, these changes in 
cellular association might be due to combination of multiple factors including receptor 
clustering,42 receptor crowding by high antibody density nanoparticles43 or steric crowding of 
18
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Figure 5. (A) Flow cytometry analysis of PSMA+ and PSMA- cells association of Cy5 labelled 
micelles with varying antibody densities (0, 5, 10, 15, 25, 50, 75, and 100%). (B) Confocal 
microscopy images of PSMA+ cells incubated with micelles of varying antibody densities (0, 
25 and 100%), along with magnified confocal images showing the distribution of micelles 
across the PSMA+ cells. 
Biodistribution and tumour accumulation of micelles with varying antibody densities in 
tumour-bearing mice. The influence of ligand density on in vivo biodistribution and tumour 
accumulation was evaluated to understand the balance between increased cell targeting (with 
increasing ligand density) and tumour accumulation. BALB/c nude mice bearing both 
19
     
     
the antibody on the nanoparticles44 which ultimately leads to difference in the association levels 
in vitro.45,46  
Interaction of a subset of the micelles (A0, A25, and A100) with both PSMA+ and PSMA- 
cells was evaluated by confocal microscopy in order to assess the effect of antibody on the 
degree of cell internalisation. The microscopy showed a similar trend to that observed in the 
flow cytometry, whereby higher uptake is observed for the A25 micelle than either the A0 or 
A100 micelle, again pointing at a receptor-mediated interaction that is modulated by ligand 
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(PSMA+) and (PSMA-) prostate cancer xenografts in their opposite flanks were administered 
micelles with varying antibody densities through I.V. injection. Mice were sacrificed and organ 
distribution of the Cy5-labelled micelles monitored by fluorescence imaging (24 and 48 h). In 
order to compare the micelles between tumour bearing mice, the fluorescence intensities were 
normalised with respect to the 100% antibody containing micelles, which has been accounted 
for in Table S1. At 24 h post-injection, the PSMA+ tumours demonstrated an antibody-
dependent micelle accumulation, showing an almost 19-fold increase in micelle accumulation 
with the increase of antibody density from 0% to 25%, owing to enhanced retention in the 
tumour (Figure 6A). However, increasing the antibody content further resulted in a decreasing 
level of tumour accumulation compared to A25, with A50, A75 and A100 micelles only 
achieving a doubling of micelle accumulation compared to A0. This decrease in accumulation 
above A25 was most likely caused by a decreased concentration of circulating micelles due to 
immune recognition of the more proteinaceous nanomaterials. Such an effect ultimately leads 
to the clearance by the mononuclear phagocytic organs such as liver and spleen. This scenario 
was confirmed by the increase in fluorescence in these organs with increasing antibody content 
(Figure 6B), thereby resulting in a decrease in overall circulating micelle content in the blood 
and consequently decreased accumulation in the tumour at longer time points. At 24 h post-
injection, the PSMA- tumour showed significantly less micelle accumulation in the tumour at 
all antibody compositions and similar to that observed for A0 (in both tumours), suggesting 
that the presence of antibody (even in the A100 sample) contributes to improvement in tumour 
tissue accumulation above that observed by the enhanced permeability and retention (EPR) 
effect alone.47 
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Figure 6. (A) Bar chart showing the average radiant efficiency of Cy5 signals from PSMA+ 
and PSMA- tumour, 24 h post-I.V. injection of micelles with varying ligand densities of 0, 5, 
10, 15, 25, 50, 75, 100% antibody content. (B) Bar chart showing the average radiant efficiency 
of Cy5 signals from other major organs, 24 h post-I.V. injection of micelles with varying ligand 
densities of 0, 5,10, 15, 25, 50, 75, 100% antibody content. (C) Bar chart showing the cellular 
association of micelles with immune cells such as leukocytes (CD45+), monocytes (CD11b+) 
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and macrophages (F4/80+) in the liver after 24 h post-I.V. injection of micelles with varying 
ligand densities of 0, 25, 50, and 100% antibody content. (n = 3 per group), (∗∗ = p < 0.01, ∗∗∗ 
= p < 0.001, ∗∗∗∗ = p < 0.0001).
A similar trend in accumulation is observed at 48 h, where the effect of passive targeting (to 
PSMA-) was slightly more prominent than the 24 h time point (Figure S15). 
Micelle association with murine immune cell populations. The ratio of PEG to antibody 
component on the surface of the micelles has a significant impact on its accumulation and 
distribution across tumour and other organs. It is crucial to understand the influence of antibody 
density on the interactions between micelles and immune cells, predominantly present in the 
liver and spleen for nanoparticles. These immune cells constitute the MPS, and upon 
stimulation results in rapid clearance of micelles from animals. We established a flow 
cytometric assay to furnish important insights into micelle distribution between different 
immune cell types in liver and spleen following injection of the micelles into 
immunocompetent mice (Figure 6C, S16 and S17). The use of a CD45 marker (to identify 
immune populations from other cell types in the organ), as well as a live/dead exclusion dye, 
provided a useful means to investigate immune-trafficking of the micellar particles. In terms 
of gating strategy, after identifying the immune cells (CD45+) from the whole cell population, 
additional markers such as CD11b and F4/80 were used to distinguish monocytes and 
macrophage subpopulations, respectively. The flow cytometry suggested a 3-fold higher 
proportion of A100 micelles in whole immune cell (CD45+) populations compared to the A0 
micelles (Figure 6C). The CD11b+ cell population includes monocytes, a subset of white blood 
cells that play a key role in homeostasis and inflammation, and can be readily transported to 
the site of inflammation.48 In the CD11b+ cell population in liver and spleen, the association 
was three- to eight-fold higher for hybrid micelles compared to polymer micelles, with 
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increasing association with greater antibody content. We also observed higher cellular 
association for F4/80+ macrophages in the case of A100 micelles. Generally, Kupffer cells and 
splenic red pulp macrophages show high levels of expression for F4/80 glycoprotein and have 
critical roles in immune surveillance, with Kupffer cells being the major route of nanoparticle 
removal from circulation.49,50 The increased immune response for A100 micelles with an 
increase in antibody content clearly indicates an active role of the immune system in 
recognising, and clearing these micelles from circulation. After I.V. injection of micelles, 
serum proteins in the blood binds to these micelles resulting in a protein corona.51-54 This 
binding depends on the surface properties of the micelles; for instance, PEGylation blocks the 
serum protein interaction resulting in lower MPS recognition. However, the presence of 
antibodies on the micelle surface triggers the serum protein interaction and thereby results in 
enhanced liver and spleen clearance. To exemplify this point, interactions between micelles 
and serum proteins were studied by incubating them in FBS containing cell culture media. In 
this experiment, the serum protein interaction was significant only for an antibody content of 
50% or higher (Figure S18) in the micelles. Furthermore, an evaluation of the micelle 
distribution in various immune cells in mice blood ex vivo was also carried out. In general, the 
higher the antibody content in the micelle, the greater the interaction with all elements of the 
immune cell populations that we investigated. Moreover, more specific association with blood 
immune cell populations, including neutrophils and monocytes, was observed at higher 
antibody concentrations (Figure S19).
Micelle accumulation in human white blood cells. A key issue in the translation of 
nanomedicines to clinical acceptance is the mismatch between observations in mouse and 
human studies. With this in mind, we next investigated the micellar association with the 
immune population of cells in whole human blood, as these will be the first host cells that 
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interact with micelles following I.V. administration.55 Human blood immune cells such as 
granulocytes (mainly neutrophils), monocytes, lymphocytes (B-cell and T cell) and dendritic 
cells were analysed after incubation with the micelles with fresh whole human blood for 1 h at 
37 °C using established methodologies previously reported by Kent et al..56 Overall, there was 
a clear modulation in immune-cell interaction as a result of increasing antibody content in the 
micelles. Association was highest for A100 and A75 micelles with granulocytes, with 
approximately 80-90% cells showing some interaction with the micelles (Figure 7A). While 
A50 micelles showed 40% association, further lowering of antibody content showed minimal 
association. This observation clearly shows immune recognition resulting from the interaction 
of antibody component with neutrophils and its phagocytic nature.55 Within the monocyte 
population, A0 micelles showed less than 1% cellular association indicating its stealth nature, 
a direct consequence of the purely PEG surface nature of this particular micelle. However, 10% 
or higher antibody content showed an increase in cellular association with >10% of cells 
showing a measurable association when the antibody component of the micelles was 50% 
(Figure 7B). Similar trends were observed for both lymphocyte populations and dendritic cells 
(gating strategy used for differentiating cell populations are shown in Figure S20). These 
results showed a direct link between the level of antibody density and immune-cell interaction, 
with an enhanced immune clearance of the micelles with ≥ 50% antibody content. These human 
ex vivo blood studies are precisely comparable to our in vivo mouse studies above, suggesting 
that the findings are likely to be transferable (at least in the broadest sense) to clinical 
assessment of nanomedicines. More importantly, these in-depth immune studies offer some 
important insight into why greater antibody density often leads to a mismatch between in vitro 
cancer cell association studies (undertaken extensively in vitro in nanomedicine research) and 
tumour accumulation and/or efficacy studies of nanotherapeutics.9 It is clear that each 
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nanomedicine needs to be assessed on a case-by-case basis, where the merit of targeting 
specific receptors present on cells is weighed against the need for stealthiness.
It is also important to consider the effects of multiple copies of a targeting agent on the cell 
surface and intracellular processing pathways more generally. Pattern recognition by the 
immune system is an important mechanism in the body’s defence against pathogens, 
particularly viruses which display multiple ligands in order to take advantage of multivalent 
interactions. Accordingly, the use of repeating patterns of protein recognition domains on a 
synthetic nanoparticle might be expected to result in increased detection by immune 
surveillance mechanisms. In addition, it has been shown that engagement of multiple receptors 
at some cancer cell surfaces can lead to clustering and changes in intracellular trafficking 
pathways leading to lysosomal accumulation.12,14 This might be detrimental for delivery of 
biotherapeutics but advantageous for lysosomally-activated pro-drugs. Therefore, it may be the 
case that an optimal targeting ligand density exists and that this will depend on the route of 
administration, the immune status of the patient, and the specific disease site and therapeutic 
agent. The results in this study provide important design criteria which might allow future 
optimisation and ultimately personalisation of nanomedicines.
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Figure 7. Effect of antibody density on the interaction of micelles with human innate immune 
cells. Histograms show the percentage cellular association of micelles with (A) Granulocytes, 
(B) Monocytes, (C) B-cells, (D) T-cells, (E) Dendritic cells at 37 °C.
CONCLUSION
We report an approach to generate a micellar nanomaterial platform with control over antibody 
fragment surface density, allowing us to study in-depth the true influence of surface 
functionalisation on both cell binding, immune recognition and tumour accumulation of 
nanomedicines. The micellar assemblies showed antibody-density dependent association and 
internalisation in cells that upregulate a receptor that binds to the antibody (PSMA receptor), 
with maximum association observed between 25 – 50% antibody surface density. The decrease 
in association at higher densities was attributed to receptor saturation or potentially clustering 
effects of the receptor on the cell surface. Moreover, when administered intravenously into 
tumour-bearing mice, significantly enhanced tumour association was observed for the micelle 
with 25% antibody density compared to all other densities. The decrease in accumulation at a 
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higher density above 25% was shown to be proportional to the increase in immune recognition 
of these species and subsequent clearance through the MPS organs. The micelles clearly 
become less “stealthy” in mice with greater antibody content, which was also confirmed by our 
ex vivo human whole blood analyses. Additionally, our studies on human white blood cells 
demonstrated that the higher antibody densities had an influence on immune cell interactions. 
These results provide an understanding of how these fundamental properties of designed 
nanoparticles can be utilised to enhance cellular uptake, and influence biodistribution in 
animals, and later into clinical settings. Moreover, it is clear that there is at least a broad level 
of agreement between mouse immune studies and the human case, suggesting translatability of 
these observations when designing nanomedicines for human use. In the cancer nanomedicine 
field, it is becoming increasingly clear that just delivering the payload to the target is not 
enough but now requires an in-depth understanding of the collateral damage these 
nanomaterials could have to healthy immune cells. Ultimately, accessing the “sweet spot” in 
terms of increasing cell-association/internalisation through increased antibody density (often a 
necessity for delivery of specific drugs, such as biologics), and minimising immune recognition 
by maintaining stealthiness, are now key attributes for developing next-generation targeted 
nanomedicines that could offer improved clinical outcomes.
EXPERIMENTAL 
Materials
Dibenzocyclooctyne-amine (DBCO, Sigma-Aldrich, ≥ 94.5%), triethylamine (Et3N, Sigma-
Aldrich, ≥ 99%), 2,2’-azobis(isobutyronitrile) (AIBN, Sigma-Aldrich, 98%), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluorochem, 99%), N-






























































the residual solvent resonances (CDCl3 1H: δ = 7.26 ppm; DMSO-d6 1H: δ = 2.50 ppm).
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Aldrich, ≥ 98%), methoxy-PEG-azide (Mn=20 kDa) (mPEG, Biochempeg, ≥ 95%), Cyanine5 
maleimide (Cy5, Lumiprobe, > 95%), phosphate-buffered saline (PBS, Astral scientific) were 
all used as received. Solvents including N,N-dimethyl-formamide (DMF), 1,4-dioxane, 
methanol, tetrahydrofuran (THF), n-hexane, and dichloromethane (CH2Cl2) were used dry 
where applicable and of reagent grade quality. Diethylene glycol methacrylate (DEGMA, 
Sigma-Aldrich, 98%) were passed through basic alumina to remove inhibitor before use. Milli-
Q water (18.2 mΩ.cm-1 at 25 °C) was used throughout. Pentafluorophenyl methacrylate 
(MAPFP) was synthesised according to Fuchs et al..57 RAFT agent 4-Cyano-4-
(ethylsulfanylthiocarbonyl) sulfanylpentanoic acid (CEPA) was synthesised according to 
Convertine et al..58 Dimethyl sulfoxide-d₆ (DMSO-d6), deuterated chloroform (CDCl3) were 
purchased from Cambridge Isotope Laboratories, Inc. Cell culture medium Roswell Park 
Memorial Institute (RPMI) 1640, foetal bovine serum (FBS), were purchased from Life 
Technologies, Mulgrave, Vic, Australia and Moregate, Brisbane, Australia respectively. 
Penicillin/streptomycin mix, trypsin, trypan blue solution and Hoescht 33342 were obtained 
from Sigma-Aldrich. Prostate cancer cells (PC3-PIP (PSMA+) and PC3 (PSMA-) cells were 
received from Dr Warren Heston.59 Tissue culture treated imaging μ-dishes with 1.5 NA 
coverslips were ordered from ibidi™.
Methods
All nanomaterials were characterised using standardised reporting methods recommended by Faria 
et al., where applicable.60 1H nuclear magnetic resonance (NMR), 19F NMR spectra were 
measured on Bruker AC 400 or 500 MHz spectrometers in CDCl3 or DMSO-d6 at 25 °C. 





























































index detector (Waters). THF was used as the mobile phase at a flow rate of 1 mL min−1 and 
polystyrene (PS) as the standards. Empower 2 (Waters) software was used for data collection 
and processing. All samples were freshly prepared before analysis and filtered through a 0.45 
μm filter to eliminate large particulates. The hydrodynamic diameters and zeta potentials of 
micelles were explored on a Nanoseries Zetasizer (Malvern 90, UK). The samples were 
analysed at a scattering angle of 90° and two different temperatures 278 and 298 K, 
respectively. Samples were filtered through 0.45 μm PTFE filters prior to measurement. UV-
Vis measurements were performed on a Nanodrop 2000C spectrophotometer (Thermo Scientific) 
using a low volume (700 μL) quartz cuvette with a 10 mm path length. Absorbance maxima were 
recorded at 309 and 647 nm for DBCO and Cy5 absorbance respectively. For transmission electron 
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microscope (TEM) imaging, particles were dissolved in water, dropped onto copper grids, and 
air-dried before imaging. Polyacrylamide gel electrophoresis (PAGE) was performed on 
Bolt™ 4-12% Bis-Tris Plus Gels (Invitrogen, Paisley, UK) equipped with a PowerPac Basic 
power supply at 200 V for 30 min in 1X NuPAGE® MES SDS Running Buffer . The 
visualisation of the Coomassie blue-stained gels was carried out on a ChemiDoc Imaging 
system, Bio-Rad. High-performance liquid chromatography (HPLC) was performed on Dionex 
HPLC-Thermo TSQ Quantum Ultra QqQ MS couple equipped with UV-visible detector and a 
reverse-phase C18 column (75 × 4.6 mm). Gradient elution from 95% Milli-Q water containing 
0.2% formic acid to 100% MeCN:H2O (8:2) with 0.2% formic acid over a time period of 30 
min with a 200 µL min-1 flow rate was used throughout. The wavelengths of 280 nm and 647 
nm were used for the detection of antibody and conjugates respectively for the analysis. 
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Size exclusion chromatography (SEC) for analysis of polymer molecular weight and dispersity 
was performed on a system consisting of a 1515 Isocratic pump (Waters), a 717 autosampler 
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Cell culture. Two human prostate cancer cell lines (PC3-PIP (PSMA+) and PC3 (PSMA-) 
were maintained in RPMI medium supplemented with 10% (v/v) FBS (heat-inactivated, 
Bovogen), 100 U mL-1 penicillin, 100 µg mL-1 Streptomycin and 2 mM L-glutamine and 
incubated at 37 °C in a humidified atmosphere of 5% CO2 in air.
Synthesis of p(DEGMA-co-MAPFP) copolymer using CEPA. DEGMA (0.3 g, 1.59 mmol), 
MAPFP (45 mg, 0.18 mmol), AIBN (1.1 mg, 6.89 × 10−3 mmol), CEPA (9.1 mg, 3.44 × 10−2 
mmol) and 660 μL dry 1,4-dioxane were placed in a Schlenk tube equipped with a magnetic 
stirrer bar. The vial was sealed with a rubber septum, and the reaction mixture was sparged 
with nitrogen for 15 min. The Schlenk tube was then placed in an oil bath and stirred at 65 °C 
for 18 h. At the completion of the reaction, the polymer was precipitated dropwise into an 
excess of n-hexane three times. Once the polymer had fully settled on the bottom of the beaker, 
the solvent was decanted from the top, and the oily residue was dried in the vacuum oven. The 
purified p(DEGMA-co-MAPFP) was characterised using 1H NMR (500 MHz, CDCl3) and 
SEC.
Modification of p(DEGMA-co-MAPFP) copolymer with CYS. The pentafluorophenyl 
esters were replaced by adding 20 eq. of CYS (46 mg, 0.454 µM) and 20 eq. of Et3N (35 mg, 
0.45 µM) to p(DEGMA-co-MAPFP) copolymer (150 mg, 0.022 µM) dissolved in DMF. The 
solution was stirred at 50 °C for 24 h. The reaction was cooled to room temperature, and DMF 
was removed in vacuo. The concentrated sample was redissolved in THF and purified by 
precipitating the polymer dropwise into an excess of n-hexane. The purified p(DEGMA-co-
MACYS) was dried under vacuum for 24 h. These polymers were characterised using 19F NMR 
(500 MHz, CDCl3) and SEC. The LCST behaviour of polymer samples after CYS modification 
were determined using a UV–vis spectrophotometer set at 500 nm. The polymeric samples 
were maintained at a concentration of 1 mg mL-1 in water and the solutions were heated from 
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low temperatures to high temperatures at a heating rate of 1 °C min-1. The temperature at which 
90% of the transmittance of the solution was observed was defined as the LCST. 
Modification p(DEGMA-co-MACYS) copolymer with DBCO-amine. p(DEGMA-co-
MACYS) copolymer (150 mg, 27.5 µM) was activated by NHS (3.5 mg, 30 µM) and EDC 
(10.5 mg, 55 µM) (molar ratio of Polymer: EDC: NHS=1:2:1.1) in CH2Cl2 at room temperature 
overnight. DBCO-amine (7.6 mg, 27.5 µM) with Et3N (3 mg, 30.3µM) was added and stirred 
for 12 h. DCM was removed by rotary evaporation at room temperature, and the product 
DBCO-p(DEGMA-co-MACYS) was redissolved in THF and precipitated into n-hexane. The 
purified DBCO-p(DEGMA-co-MACYS) was dried under vacuum for 24 h and characterised 
using 1H NMR (500 MHz, DMSO-d6), SEC and UV analysis
Conjugation of DBCO-p(DEGMA-co-MACYS) with Cy5 maleimide. DBCO-p(DEGMA-
co-MACYS) copolymer (150 mg, 21.7 µM) was reacted with Cy5 maleimide (1.4 mg, 2.17 
µM ) in CH2Cl2 at room temperature for 12 h. DCM was removed by rotary evaporation at 
room temperature, and the product was redissolved in THF and precipitated into n-hexane. The 
purified DBCO-p(DEGMA-co-MACYS) with Cy5 maleimide was dried under vacuum for 24 
h and characterised using UV analysis.
Conjugation of DBCO-p(DEGMA-co-MACYS) with scFv azide. Before the conjugation 
reaction, DBCO-p(DEGMA-co-MACYS) copolymer was dissolved in PBS and kept for 
stirring at 4 °C for 1 h. Then, the azide-functional scFv was added to the DBCO-p(DEGMA-
co-MACYS) copolymer solution, and the mixture was allowed to react at 4 °C for 24 h. For a 
typical preparation, 5 mg of DBCO-p(DEGMA-co-MACYS) copolymer (0.72 µmol) and 0.89 
µg of scFv (3.5 × 10−2 µmol) were used (Polymer to scFv azide ratio of ~ 20:1). After 
conjugation, samples were heated to temperature above LCST, 30 °C for 10 min, which made 
the polymer insoluble. Upon centrifugation (14,100 rcf for 10 min) the hybrid conjugate formed 
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a pellet, and unreacted scFv remained in the supernatant. This pellet was redissolved in PBS at 
4 °C and centrifuged at 9,800 rcf for 10 min using Amicon® Ultra 0.5 mL Centrifugal Filters 
(MWCO: 30 kDa) to remove any unbound polymer from the hybrid conjugate. The final 
concentrate was freeze-dried and re-dissolved for further characterisation using PAGE and 
HPLC analysis.
Conjugation of DBCO-p(DEGMA-co-MACYS) with mPEG azide. For the synthesis of 
polymer conjugate, the DBCO-p(DEGMA-co-MACYS) copolymer was dissolved in PBS and 
kept stirring at 4 °C for 1 h. Then, mPEG-azide was added to the DBCO-p(DEGMA-co-
MACYS) copolymer solution, and the mixture was allowed to react at 4 °C for 24 h. For a 
typical preparation, 4.1 mg of DBCO-p(DEGMA-co-MACYS) copolymer (0.6 × 10−6 mol), 
and 6 mg of mPEG-azide (0.3 × 10−6 mol) were used (Polymer to mPEG azide ~ 2:1). After 
conjugation, samples were heated to temperature above LCST, 30 °C for 10 min, which made 
the polymer insoluble. Upon centrifugation (14,100 rcf for 10 min), the polymer conjugate 
formed a pellet, and unreacted PEG remained in the supernatant, which could be removed. This 
pellet was redissolved in PBS at 4 °C and centrifuged at 9,800 rcf for 10 min using Amicon® 
Ultra 0.5 mL Centrifugal Filters (MWCO: 30 kDa) to remove any unbound polymer from the 
polymer conjugate. The final concentrate was freeze-dried and re-dissolved for further 
characterisation using SEC analysis.
Flow cytometry-based cellular association analysis of conjugates using a mono cell 
culture. PSMA+ cells were removed from tissue culture flasks by adding trypsin and 
resuspended in Dulbecco’s PBS (DPBS) at pH 7.4 followed by centrifugation at 131 rcf for 5 
min. The cell pellet was resuspended in 10% FCS-PBS to give 2 x 106 cells/mL. 100 μL of the 
cell suspension was aliquoted into 1.5 mL tubes and stored on ice. 10 µg mL-1 of hybrid 
conjugate and PEG conjugate were added to the 100 μL cell suspension and incubated for 60 
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min on ice. Following incubation, the cells were centrifuged gently at 131 rcf for 5 min, the 
supernatant was pipetted off and 200 μL of 10% FCS-PBS added. This wash step was repeated 
two more times. After the third and final wash, the supernatant was removed from the cells, 
and the pellet was resuspended in 100 μL of 10% FCS-PBS. For each sample, data were 
acquired for 10,000 events using a flow cytometer (BD Accuri™ C6, BD Biosciences, 
Australia) by measuring Cy5 fluorescence intensity along with the forward and side scatter. A 
similar protocol was used for the analysis of PSMA- cells.  
Synthesis of polymeric micelles by crosslinking and its characterisation. The hybrid and 
PEG conjugates were dissolved in different ratios in PBS and kept for stirring at 4 °C for 2 h. 
The solution temperature was then increased slowly to 30 °C under constant stirring. Oxygen 
was sparged into the solution for 12 h to facilitate disulfide crosslinking. Micelle confirmation 
and size were then determined by DLS and TEM. The zeta potential distribution of the micelles 
were determined using Zetasizer. Micelles of different antibody densities (0, 5, 10, 15, 25, 50, 
75 and 100%) were synthesised by a similar protocol.
Interaction of micelles with serum proteins. For serum protein-micelle interaction studies, 
100 μL of 1 mg mL-1 micelles were incubated with 400 μL of cell culture media (containing 
10% FBS) for 1 h incubation at 37 °C. Samples were then centrifuged at 14,100 rcf for 4 min, 
to pellet the protein-bound micelles. The amount of unbound serum protein remaining in the 
supernatant was then measured by the method of Bradford assay. Briefly, 100 μL of supernatant 
was taken in triplicate aliquots, and 100 μL of Bradford reagent was added. Samples were 
mixed and incubated at 37 °C for 30 min, followed by measurement of absorbance at 595 nm. 
The absorbance values were normalised against the control sample.
Stability analysis of micelles with 50% serum proteins. For the stability analysis of micelles,   
500 μL of 1 mg mL-1 micelles were incubated with 1500 μL of cell culture media (containing 
33





























































620Ex/670Em was used to analyze Cy5 fluorescence by micelles. Furthermore, A25 and A100 
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micelles were incubated in 50% serum containing media for 48 h, followed by centrifugation 
at 9,800 rcf for 10 min using Amicon® Ultra 0.5 mL Centrifugal Filters (MWCO: 3 kDa). The 
amount of Cy5 dye content in the sample was analysed at 647 nm using UV analysis.  
Flow cytometry-based cellular association analysis of micelles using a mono cell culture. 
PSMA+ cells were seeded in a 12-well plate at a concentration of 5 × 104 cells mL-1 and then 
incubated in 1 mL of RPMI media for 24 h to allow cells to adhere. Cellular association of the 
micelles into cells was then measured using flow cytometry after 1 h of exposure to 10 µg mL-1 
of micelles of varying antibody densities (0, 5, 10, 15, 25, 50, 75 and 100%). Cells were 
removed from culture dishes by addition of trypsin and resuspended in Dulbecco’s PBS 
(DPBS) at pH 7.4 followed by centrifugation at 131 r.c.f. for 5 min. The supernatant was then 
removed, and cells were resuspended in 1 mL of DPBS. For each sample, data were acquired 
for 10,000 events using a flow cytometer (BD Accuri™ C6, BD Biosciences, Australia) by 
measuring Cy5 fluorescence intensity along with the forward and side scatter. A similar 
protocol was used for the analysis of PSMA- cells. Furthermore, for competition assay, 
PSMA+ cells were pretreated with 10 µg mL-1 of J591 scFv for 30 min, following similar 
protocol as mentioned above. Cellular association of the A25 and A100 micelles into PSMA+ 
cells were also carried out using flow cytometry after 1 h of exposure to varying concentrations 
of micelles (1 − 100 µg mL-1).
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50% FBS) for 48 h incubation at 37 °C. Samples were then analysed using DLS for size and 
stability assessments. 100 μL of A0 sample (0.5 mg mL-1) was taken in 96 well plate, 100 μL 
of cell culture media (containing 50% FBS) were added and incubated for 48 h at 37 °C. 
Samples were then analysed using IVIS Lumina X5 imaging system (PerkinElmer Inc., 
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Evaluation of intracellular distribution and localisation of micelles using confocal 
microscopy. Prior to imaging, PSMA+ cells were plated into Ibidi™ µ-dishes and incubated 
with 2 mL of RPMI media overnight. Cells were then exposed to 10 µg mL-1 of A0, A25 and 
A100 micelles, incubated for 1 h followed by PBS wash to remove unbound micelles. Samples 
were imaged with an inverted Confocal Laser Scanning Microscope (Leica LASX TCS SP8) 
housed at the Australian Nanofabrication Facility (ANFF). In order to identify the distribution 
of the micelles inside the cells, the nucleus was stained using Hoechst 33342 dye (excitation 
405 nm, emission 416 - 487 nm). The 633 nm laser was used for excitation of the Cy5-labelled 
polymer micelles, and the emission was collected between 645 - 680 nm.
Animal studies and tumour model. All animal experiments were approved by the University 
of Queensland’s Animal Ethics Committee and conformed to the guidelines of the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes. For all animal 
models, eight-week-old Balb/c nude mice were acquired from the Animal Resource Centre and 
were allowed access to food and water ad libitum throughout the course of the experiment. 
In vivo biodistribution of micelles with varying antibody densities in tumour bearing mice 
using optical imaging. A total of 50 Balb/c nude mice were used in this study. To establish 
subcutaneous tumours for in vivo targeting experiments, mice were anaesthetised using 2% 
isoflurane and injected subcutaneously with 2 × 106 PSMA+ cells (left flank) and 2 × 106 
PSMA- cells (right flank), each in 100 μL serum-free media using a 27 G needle. Tumours 
were allowed to grow for 15 days before imaging experiments, at which time all mice had 
palpable tumours 5 – 10 mm in diameter. Micelles of varying antibody densities (0, 5, 10, 15, 
25, 50, 75, and 100%) were diluted in PBS to 2.5 mg mL-1, 100 µL of samples were 
administered I.V. injections via the tail vein. To investigate the accumulation of micelles into 
the tumour, mice were sacrificed after 24 and 48 h; PC3-PIP, PC3 tumour and the major organs 
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fluorescence by micelles. The fluorescence intensities were normalised with respect to the 
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100% antibody-containing micelles, which has been accounted for in Table S1.
Immune cell activation analysis with mice immune cells. Flow cytometry analysis were 
carried out according to the protocol by Brown et al.61 Single-cell suspensions from adult 
spleen or a single lobe of liver were prepared by mechanical dissociation and straining cells 
through a 70 μm nylon strainer, using a sterile syringe plunger, into tubes containing tonicity-
phosphate-buffered saline/2% fetal calf serum (PBS). Single-cell suspensions of spleen or liver 
containing immune cells of interest were pre-incubated with FVS (live-dead stain, BD 
Horizon™) for 20 min at room temperature in the dark, followed by blocking with Fc block 
(1% TruStain fcX™ (anti-mouse CD16/32; BioLegend) in PBS containing 5% rat serum) for 
10 min to block Fc receptor binding prior to surface staining with antibodies to mouse CD45, 
F4/80 and CD11b (BioLegend) for 1 h on ice in the dark. Cells were analyzed on a Fortessa 
X20 flow cytometer (BD Biosciences, Franklin Lakes, NJ) followed by data analysis with 
FlowJo software (Tree Star, 156 Inc., Ashland, OR). Furthermore, the immune cell analysis of 
mice blood cells ex vivo were also analysed. Micelles with varying antibody densities were 
added to mice blood samples and the samples were incubated for 1 h at 37 °C. Red blood cells 
were lysed and cells were phenotyped on ice for 30 min using titrated concentrations of 
antibodies against CD11b, Ly6G, CD3 and CD19 (BioLegend). Cells were analyzed on a 
Fortessa X20 flow cytometer (BD Biosciences, Franklin Lakes, NJ) followed by data analysis 
with FlowJo software (Tree Star, 156 Inc., Ashland, OR).
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Immune cell activation analysis with Human White Blood Cells. Fresh blood was collected 
from a healthy human volunteer (47 year old Female) into sodium heparin vacuettes (Greiner 
Bio-One) after obtaining informed consent in accordance with the University of Melbourne 
Human ethics approval 1647326.1 and the Australian National Health and Medical Research 
Council Statement on Ethical Conduct in Human Research. Micelles with varying antibody 
densities were added to human blood samples, such that their concentration in blood was 2 µg 
mL-1, and the samples were incubated for 1 h at 37 °C. Red blood cells were lysed by adding 
Pharm Lyse buffer (BD) and incubated for 15-30 min in ice and washed twice with PBS (500 
g, 7 min). Cells were phenotyped on ice for 30 min using titrated concentrations of antibodies 
against CD66b BV421 (G10F5, BD), CD14 APC-H7 (MΦP9, BD), CD19 BV650 (HIB19, 
Biolegend), CD3 AF700 (SP34-2, BD), CD56 PE (B159, BD), HLA-DR PerCP-Cy5.5 (G46-
6, BD), lineage-1 cocktail FITC (BD). Unbound antibodies were removed by washing and 
centrifugation (500 g, 7 min) with a cold (4 °C) PBS buffer containing 0.5% w/v BSA and 2 
mM EDTA. Cells were fixed in 1% w/v formaldehyde in PBS. The samples were directly used 
for cell association analysis by flow cytometry. The data were processed using FlowJo 
software.
Statistical analysis
Data for each measurement represent mean ± standard deviation, n = 3. Statistical analysis was 
performed using Graphpad Prism 8.1 software. The statistical comparisons were conducted 
using One-way ANOVA or Two-way ANOVA, followed by the Tukey multicomparison test. 
P values < 0.05 were considered statistically significant (∗ = p < 0.05, ∗∗ = p < 0.01, ∗∗∗ = p < 
0.001, ∗∗∗∗ = p < 0.0001). 
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1H NMR of polymer precursors, turbidity scans showing LCST behaviour of polymers, SDS-
PAGE conjugate analysis, DLS size data of mPEG and scFv, cell association assays for 
conjugates, DLS size data of conjugates in serum, DLS size, zeta and stability analysis of 
micelles, competition assay of the micelles, fluorescence images of organs following injection 
of various constructs, micelle interaction with serum proteins in serum, interaction of micelles 
with immune cells in mice blood
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